483
Synapse Biomedical IncSynapse Biomedical Inc – FDA 483, Oct 7, 2020
Record Details
An FDA inspection of Synapse Biomedical Inc. in Oberlin, OH, revealed significant deficiencies in their quality system for medical device manufacturing. The firm failed to adequately validate critical processes, including sterile packaging and cleaning, and exhibited inadequate risk analysis for its NeuRx diaphragm stimulating device. Additionally, issues were noted in documenting non-conforming products, acceptance activities, and establishing clear procedures for supplier evaluation.
View Company Profile
ID · 7f938384-7e08-4a1a-9e20-baa8c0d27a76
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.